Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Chinese Lung Cancer Surgical Group
- Target Recruit Count
- 80
- Registration Number
- NCT01410214
- Locations
- 🇨🇳
The Second People's Hospital of Sichuan, Chengdu, Sichuang, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 72
- Registration Number
- NCT01407822
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
- Conditions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Markus Joerger
- Target Recruit Count
- 54
- Registration Number
- NCT01402089
- Locations
- 🇨🇭
Cantonal Hospital St.Gallen, St.Gallen, Switzerland
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01378962
- Locations
- 🇮🇹
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy
🇮🇹Istituto Regina Elena; Oncologia Medica A, Roma, Lazio, Italy
🇮🇹A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 485
- Registration Number
- NCT01351415
- Locations
- 🇺🇸
University of Pennsylvania; Radiation Oncology, Philadelphia, Pennsylvania, United States
🇯🇵Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan
🇺🇸USA Mitchell Cancer Institute, Mobile, Alabama, United States
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 217
- Registration Number
- NCT01342965
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 643
- Registration Number
- NCT01328951
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- National Guard Health Affairs
- Target Recruit Count
- 100
- Registration Number
- NCT01320501
- Locations
- 🇸🇦
King Abdul Aziz Medical City for National Guard Health Affairs, Riyadh, Saudi Arabia
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01310036
- Locations
- 🇨🇳
Changhua Christian Hospital; Internal Medicine, Changhua, Taiwan
🇨🇳Veterans General Hospital; Internal Medicine, Kaohsiung, Taiwan
🇨🇳Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 647
- Registration Number
- NCT01306045
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.